2invest AG
SYGNIS AG signs non-exclusive distribution agreement with Scandinavian Biotop Oy for Finland
SYGNIS AG / Key word(s): Miscellaneous
Press Release
SYGNIS AG signs non-exclusive distribution agreement with Scandinavian Biotop Oy for Finland – Biotop is a leading Scandinavian life science distributor focused on molecular biology and cell biology – Distribution agreement covers SYGNIS’ complete portfolio for DNA sample processing for next generation sequencing (NGS) and single cell analysis applications Madrid, Spain and Heidelberg, Germany, June 17th, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed a non-exclusive distribution agreement for the commercialization of SYGNIS’ proprietary product portfolio with Biotop Oy for Finland. Under the terms of the agreement, SYGNIS has granted Biotop the non-exclusive rights to promote, market and sell TruePrime(TM) products for primer-free DNA-amplification as well as SunScript(TM) thermostable reverse transcriptase kits for the translation of RNA into DNA to scientists working in the wide field of molecular biology in Scandinavia. TruePrime(TM) products are based on the combination of SYGNIS’ proprietary DNA primase “TthPrimPol” and the Phi29 polymerase, which allows the amplification of total genomic DNA from smallest amounts of samples down to single cells without the need of random synthetic primers. SYGNIS’ SunScript(TM) product line covers a series of kits based on a proprietary reverse transcriptase (RT) which today is one of the most thermostable and fastest enzymes commercially available. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling a number of downstream analyses of RNA molecules using DNA analysis methods such as NGS or polymerase chain reaction (PCR) in gene expression profiling and molecular diagnostics. Biotop is a specialist provider offering a broad portfolio of innovative research reagents for the wide field of molecular biology as well as cell biology applications including next generation sequencing applications to customers in Finland. Beside the worldwide commercialization via a fast growing list of leading international distribution partners, the product portfolio can also be directly ordered through SYGNIS’ own online shop under http://www.sygnis.com/shop. About TruePrime(TM) TruePrime(TM) is the brand name of a revolutionary novel multiple displacement amplification technology and one of the key products in SYGNIS’ portfolio. TruePrime(TM) is based on the combination of SYGNIS proprietary DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers. About SunScript(TM) RT SunScript(TM) Reverse Transcriptase is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85 C. SunScript(TM) Reverse Transcriptase will be available in two versions: SunScript(TM) RT RNaseH+ is optimized for the synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions whereas SunScript(TM) RT RNaseH- permits high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing applications. For further information please contact:
About SYGNIS AG: www.sygnis.com Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi(R), licensed to an industry leading partner and two own product lines on the market: TruePrime(TM) based on its proprietary TruePrime(TM) technology for whole genome amplification and SunScript(TM) Reverse Transcriptase to convert genetic information from RNA molecules back to DNA. Both product lines are addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications. ### Disclaimer This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.### 2015-06-17 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | SYGNIS AG | |
Im Neuenheimer Feld 515 | ||
69120 Heidelberg | ||
Germany | ||
Phone: | 06221 454-6 | |
Fax: | 06221 454-700 | |
E-mail: | contact@sygnis.de | |
Internet: | www.sygnis.de | |
ISIN: | DE000A1RFM03 | |
WKN: | A1RFM0 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News-Service |
368853 2015-06-17 |